-
1.Oral formulations of mitochondrially-targeted antioxidants and their preparation and use 有权
标题翻译: 线粒体靶向抗氧化剂的口服制剂及其制备和用途公开(公告)号:US09192676B2
公开(公告)日:2015-11-24
申请号:US14123311
申请日:2012-06-04
申请人: Maxim V. Skulachev , Vladimir P. Skulachev , Andrey A. Zamyatnin , Eugeny S. Efremov , Innokentiy V. Skulachev , Vadim N. Tashlitsky , Roman A. Zinovkin , Maxim V. Egorov , Lawrence T. Friedhoff , Olga Y. Pletushkina , Alexander A. Andreev-Andrievsky , Tatiana V. Zinevich
发明人: Maxim V. Skulachev , Vladimir P. Skulachev , Andrey A. Zamyatnin , Eugeny S. Efremov , Vadim N. Tashlitsky , Roman A. Zinovkin , Maxim V. Egorov , Lawrence T. Friedhoff , Olga Y. Pletushkina , Alexander A. Andreev-Andrievsky , Tatiana V. Zinevich
IPC分类号: A61K31/66 , A61K47/26 , A61K31/352 , A61K31/4375 , C07F9/54 , A61K47/10 , A61K47/12 , A61K9/00 , A61K47/36 , A61K47/14
CPC分类号: A61K47/48084 , A61K9/0095 , A61K31/047 , A61K31/122 , A61K31/352 , A61K31/4375 , A61K31/66 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/36 , A61K47/545 , A61K47/548 , C07F9/5435 , C07F9/5442 , C07F9/5456
摘要: Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.
摘要翻译: 提供了氧化和还原的线粒体靶向抗氧化剂的稳定的液体和固体制剂及其制备和使用的方法。
-
2.ORAL FORMULATIONS OF MITOCHONDRIALLY-TARGETED ANTIOXIDANTS AND THEIR PREPARATION AND USE 有权
标题翻译: 麻醉剂抗氧化剂的口服制剂及其制备和使用公开(公告)号:US20150025043A1
公开(公告)日:2015-01-22
申请号:US14123311
申请日:2012-06-04
申请人: Maxim V. Skulachev , Vladimir P. Skulachev , Andrey A. Zamyatnin , Vadim N. Tashlitsky , Roman A. Zinovkin , Maxim V. Egorov , Lawrence T. Friedhoff , Olga Y. Pletushkina , Alexander A. Andreev-Andrievsky , Tatiana V. Zinevich
发明人: Maxim V. Skulachev , Vladimir P. Skulachev , Andrey A. Zamyatnin , Eugeny S. Efremov , Vadim N. Tashlitsky , Roman A. Zinovkin , Maxim V. Egorov , Lawrence T. Friedhoff , Olga Y. Pletushkina , Alexander A. Andreev-Andrievsky , Tatiana V. Zinevich
IPC分类号: A61K47/26 , A61K31/352 , A61K47/14 , A61K47/10 , A61K47/12 , A61K31/66 , A61K31/4375
CPC分类号: A61K47/48084 , A61K9/0095 , A61K31/047 , A61K31/122 , A61K31/352 , A61K31/4375 , A61K31/66 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/36 , A61K47/545 , A61K47/548 , C07F9/5435 , C07F9/5442 , C07F9/5456
摘要: Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.
摘要翻译: 提供了氧化和还原的线粒体靶向抗氧化剂的稳定的液体和固体制剂及其制备和使用的方法。
-
公开(公告)号:US07105540B2
公开(公告)日:2006-09-12
申请号:US10253731
申请日:2002-09-24
IPC分类号: A61K31/445 , A61K31/55 , A61K31/40 , A61K31/497 , A61K31/415
CPC分类号: A61K31/445
摘要: The present invention provides novel methods of treating disorders of attention or improving attention in humans by administering an effective amount of a cholinesterase inhibitor.
-
公开(公告)号:US06455544B1
公开(公告)日:2002-09-24
申请号:US09033880
申请日:1998-03-03
IPC分类号: A61K31445
CPC分类号: A61K31/445
摘要: The present invention provides novel methods of treating disorders of attention or improving attention in humans by administering an effective amount of a cholinesterase inhibitor.
摘要翻译: 本发明提供了通过施用有效量的胆碱酯酶抑制剂来治疗人的注意障碍或改善注意力的新方法。
-
5.Method of preventing or reducing adverse reactions to protamine using a thromboxane A.sub.2 receptor antagonist 失效
标题翻译: 使用巯基A2受体拮抗剂预防或减少不利反应的方法公开(公告)号:US5066480A
公开(公告)日:1991-11-19
申请号:US179694
申请日:1988-04-11
IPC分类号: A61K31/00 , A61K31/19 , A61K31/335 , A61K31/557 , A61K45/06 , A61P9/12 , A61P11/00 , A61P43/00
CPC分类号: A61K31/19 , A61K31/00 , A61K31/557 , Y10S514/823 , Y10S514/922
摘要: A method is provided for preventing reducing or reversing adverse reactions, such as pulmonary hypertension produced when protamine interacts with heparin, by administering a thromboxane A.sub.2 receptor antagonist.
-
6.Method of treating skin injuries using thromboxane A.sub.2 receptor antagonists 失效
标题翻译: 使用血栓素A2受体拮抗剂治疗皮肤损伤的方法公开(公告)号:US4925873A
公开(公告)日:1990-05-15
申请号:US239376
申请日:1988-09-01
IPC分类号: A61K31/00 , A61K31/19 , A61K31/195 , A61K31/557 , A61K45/00 , A61P3/00 , A61P17/00
CPC分类号: A61K31/00 , A61K31/19 , A61K31/557
摘要: A method for treating skin injuries is provided by administering a thromboxane A.sub.2 receptor antagonist systemically or topically to the skin area to be treated.
-
-
-
-
-